智通财经APP讯,汇宇制药(688553.SH)发布公告,公司全资子公司四川汇宇海玥医药科技有限公司(以下简称“汇宇海玥”)自主研发的1类生物创新药注射用HY0001a(项目研发代号为“HY-0001”)正在开展用于治疗晚期实体瘤的I期临床试验,于近日成功完成首例受试者给药。
注射用HY0001a是公司全资子公司汇宇海玥自主研发的一种抗体偶联药物,其注册分类为1类创新型治疗用生物制品。截至本公告披露日,国内外尚无同靶点产品获批上市。
研究表明,CDCP1在胃癌、乳腺癌、肺癌、结直肠癌、胰腺癌等多种肿瘤中高表达而正常组织不表达或低表达,是ADC药物开发的重要潜力靶点。临床前研究表明,HY0001a在多种实体瘤模型中表现出优秀的抗肿瘤效果且安全性良好,具有巨大的临床开发价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.